Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2012. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the GlaxoSmithKline Annual Investment Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of a specific share transaction rather than a financial performance report.
Material Changes
No material changes to financial performance or operations are reported in this filing. The only reported activity is an increase in shareholding by a director through dividend reinvestment.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It strictly details a transaction executed on January 18, 2012, where Dr. M M Slaoui acquired 307 ordinary shares at 1463 pence per share following the reinvestment of a dividend paid on January 5, 2012.
Key Facts for Investor Verification
- Director Dr. M M Slaoui increased his ordinary shareholding by 307 shares.
- The transaction price was 1463 pence per share.
- The purchase was funded by the reinvestment of a dividend paid on January 5, 2012.
- The transaction was notified to the company on January 19, 2012, in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).